Monitor for actual share sales under this ATM facility, as the timing and volume will impact dilution and stock price. The lack of specific use of proceeds and the company's early-stage status with no revenue suggest this is primarily a liquidity play rather than funding for specific near-term value-creating initiatives.
Price Chart
Executive Summary
Regencell Bioscience Holdings Ltd (RGC) has established an at-the-market (ATM) offering facility with Univest Securities to sell up to $500 million in ordinary shares. The offering allows the company to raise capital incrementally based on market conditions, with no obligation to sell any specific amount. The proceeds will be used for working capital, capital expenditures, and general corporate purposes, including potential strategic transactions.
Key Facts
- Company established an ATM offering facility with Univest Securities to sell up to $500 million in ordinary shares
- Sales will be made at market prices from time to time, with no obligation to sell any specific amount
- Proceeds will be used for working capital, capital expenditures, and general corporate purposes
- Company is an early-stage bioscience company focused on Traditional Chinese Medicine for neurocognitive disorders
- No revenue generated from TCM formula and no regulatory approvals obtained yet
- Company faces going concern uncertainty with accumulated deficit of $25.2 million as of June 30, 2025
Financial Impact
Up to $500,000,000 in potential capital raised through at-the-market offerings
Risk Factors
- Significant dilution to existing shareholders as new shares are issued
- Going concern uncertainty due to accumulated deficit and lack of revenue
- No guarantee that any shares will be sold under the ATM facility
- Company's TCM formula is still in development with no regulatory approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-035916 |
| Document: ea028290901ex-fee.htm | 0001213900-26-035916 |
| Document: 0001213900-26-035916-index-headers.html | 0001213900-26-035916 |
| Document: 0001213900-26-035916-index.html | 0001213900-26-035916 |
| Document: 0001213900-26-035916.txt | 0001213900-26-035916 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 20-F | $7.63 $7.35 | ▲ +3.67% | ▲ +4.27% | $6.76 (+11.40%) |
May 22, 2026 22w ago | 6-K | $25.80 $24.31 | ▲ +5.78% | ▲ +6.36% | $6.76 (+73.80%) |
May 19, 2026 22w ago | 424B5 | $27.39 $27.00 | ▲ +1.42% | ▲ +1.62% | $6.76 (+75.32%) |
May 19, 2026 22w ago | 6-K | $27.00 $27.39 | ▲ +1.44% | ▲ +0.40% | $6.76 (−74.96%) |
May 8, 2026 24w ago | 6-K | $27.33 $26.35 | ▲ +3.59% | ▲ +3.45% | $6.76 (+75.27%) |
Apr 17, 2026 27w ago | 6-K | $28.10 $28.40 | ▼ −1.07% | ▼ −1.72% | $6.76 (+75.94%) |
Mar 30, 2026 30w ago | 6-K | $23.33 $25.43 | ▲ +9.00% | ▲ +6.11% | $6.76 (−71.02%) |
Mar 30, 2026 30w ago | 6-K | $23.33 $25.43 | ▲ +9.00% | ▲ +6.11% | $6.76 (−71.02%) |
Mar 30, 2026 30w ago | 424B5 | $23.33 $25.43 | ▲ +9.00% | ▲ +6.11% | $6.76 (−71.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers